Atrial FibrillationNCT05295056
Clinical Performance of the AFGen1 Device Over a 7-day Period
An observational study of Atrial Fibrillation and Afib, run by TriVirum, Inc. at 1 site in United States.
Trial summary
AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. Read more about this study
- Who is it for?
- Ages 65 to 90 years
- Conditions the study is for
- Atrial Fibrillation, Afib, Irregular Heart Beat
- What is being tested?
- AFGen1 Device Wear Test and AFGen 1 Device Single Use
- Type of treatment
- Medical device
- How many people
- 38 participants
- Where
- 1 siteUnited States
- Study dates
- 12 May 2022to 25 Aug 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 90 years
- All sexes
- Older adult
Study population: The study shall involve approximately 30-50 participants (approximately equal number of males and females, equal number with BMI < and > 35) meeting inclusion and exclusion criteria.
Who may be able to join
- 1. 18+ willing to sign the consent form
Who cannot join
- Implanted pacemakers
- Implanted cardioverter defibrillators
- Implanted cardiac resynchronization devices
- Potential life-threatening arrythmias
- Physical or mental health conditions that would prevent the person from being able to follow instruc-tions regarding participation in the study
- Open wounds, abraded or irritated skin at the application site
- Planned to undergo a MRI during the course of the study duration
Trial locations and contacts
1 site in 1 country.
About this study
AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish the clinical performance of the AFib-Chek device (a.k.a. Device) on human participants.
Read the detailed description
The primary purpose of this study is to demonstrate that the ECD signal acquired by the AFGen1 device is as of adequate quality and is suitable to support its intended use for the detection of AFib.
- Conditions
- Atrial Fibrillation, Afib, Irregular Heart Beat, Arrhythmias, Cardiac, Arrhythmia Atrial, Arrhythmias Paroxysmal
- Being tested
- AFGen1 Device Wear Test, AFGen 1 Device Single Use
- Medical subject headings
- Atrial Fibrillation, Arrhythmias, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AFGen1 Device Wear TestDevice
Participant wears the device for 7 days
AFGen 1 Device Single UseDevice
Participant wears the device in conjunction with a standard ECG
| Study group | Role | What they receive |
|---|---|---|
| Permanent atrial fibrillation | Known to have permanent atrial fibrillation Receives: Device: AFGen1 Device Wear Test | |
| Healthy control | Healthy controls Receives: Device: AFGen1 Device Wear Test; Device: AFGen 1 Device Single Use |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantitative Evaluation
For the quantitative evaluation of the mean and standard deviation of the QRS correlations for all study subjects and for the end of the wear period for those relevant subjects, the mean cor- relation coefficient must be greater than 0.95 and standard deviation must be less than 0.05 to validate a 95% confidence interval with significant factor of assurance.
Measured: 7 days
Qualitative Equivalence Evaluation
For the qualitative equivalence evaluation according to the two cardiologists the confirmation of equivalence must be greater than 95%.
Measured: 7 days
Adhesive performance
For the adhe sive performance element of the stud y; t he overall average wear time for the de- vice must be greater than 5 days
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2022
- Study start12 May 2022
- Primary completion25 Aug 2023
- Study completion25 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- TriVirum, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05295056
- Sponsor's protocol ID
- AFib-Chek-001
- Status last verified
- Sep 2023
- First submitted
- 15 Mar 2022
- Last updated
- 28 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Performance of the AFGen1 Device Over a 7-day Period
- ClinicalTrials.gov ID
- NCT05295056
- Acronym / sponsor ID
- AFib-Chek-001
- Conditions
- Atrial Fibrillation, Afib, Irregular Heart Beat, Arrhythmias, Cardiac, Arrhythmia Atrial, Arrhythmias Paroxysmal
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 38 participants (actual)
- Lead sponsor
- TriVirum, Inc.Industry (pharma, biotech, devices)
- Study start
- 12 May 2022 (actual)
- Primary completion
- 25 Aug 2023 (actual)
- Study completion
- 25 Aug 2023 (actual)
- First posted
- 24 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish the clinical performance of the AFib-Chek device (a.k.a. Device) on human participants.
Detailed description
The primary purpose of this study is to demonstrate that the ECD signal acquired by the AFGen1 device is as of adequate quality and is suitable to support its intended use for the detection of AFib.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Permanent atrial fibrillation | – | Device: AFGen1 Device Wear TestKnown to have permanent atrial fibrillation |
| Healthy control | – | Device: AFGen1 Device Wear Test, Device: AFGen 1 Device Single UseHealthy controls |
Who may qualify
- Ages
- 65 to 90 years
- Sex
- All
- Age groups
- Older adult
- Study population
- The study shall involve approximately 30-50 participants (approximately equal number of males and females, equal number with BMI < and > 35) meeting inclusion and exclusion criteria.
Key inclusion criteria (1 listed)
- 1. 18+ willing to sign the consent form
Key exclusion criteria (7 listed)
- Implanted pacemakers
- Implanted cardioverter defibrillators
- Implanted cardiac resynchronization devices
- Potential life-threatening arrythmias
- Physical or mental health conditions that would prevent the person from being able to follow instruc-tions regarding participation in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AFGen1 Device Wear TestParticipant wears the device for 7 days | Device | Healthy control, Permanent atrial fibrillation |
| AFGen 1 Device Single UseParticipant wears the device in conjunction with a standard ECG | Device | Healthy control |
Primary outcome
Quantitative Evaluation
Time frame: 7 days
For the quantitative evaluation of the mean and standard deviation of the QRS correlations for all study subjects and for the end of the wear period for those relevant subjects, the mean cor- relation coefficient must be greater than 0.95 and standard deviation must be less than 0.05 to validate a 95% confidence interval with significant factor of assurance.
Qualitative Equivalence Evaluation
Time frame: 7 days
For the qualitative equivalence evaluation according to the two cardiologists the confirmation of equivalence must be greater than 95%.
Adhesive performance
Time frame: 7 days
For the adhe sive performance element of the stud y; t he overall average wear time for the de- vice must be greater than 5 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2023.
- Individual participant dataSharing planned: No
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation and Afib, run by TriVirum, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantitative Evaluation (time frame: 7 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.